Ticker Details
REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
IPO Date:	September 17, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$462.45M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.76 | 2.90%
Avg Daily Range (30 D):	$0.28 | 3.19%
Avg Daily Range (90 D):	$0.37 | 3.26%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.66M
Avg Daily Volume (90 D):	.7M

Trade Size
Avg Trade Size (Sh.):	73
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	3,401
Avg Institutional Trade:	$1.92M
Avg Institutional Trade (30 D):	$1.17M
Avg Institutional Trade (90 D):	$1.3M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.14M
Avg Closing Trade (30 D):	$1.05M
Avg Closing Trade (90 D):	$1.08M
Avg Closing Volume:	82.94K

News

Apr 6, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO ... Source: Bronstein, Gewirtz & Grossman Llc

Apr 6, 2026 @ 8:04 AM RGNX Investors Have Opportunity to Lead REGENXBIO ... Source: The Schall Law Firm

Apr 5, 2026 @ 11:52 PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENX... Source: Rosen Law Firm

Apr 5, 2026 @ 11:29 PM TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL... Source: Rosen Law Firm

Apr 5, 2026 @ 1:12 AM ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENX... Source: Rosen Law Firm

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.76	$-1.3	$-3.76
Diluted EPS	$-3.76	$-1.3	$-3.76
Revenue	$170.44M	$30.34M	$170.44M
Gross Profit
Net Income / Loss	$-193.88M	$-67.15M	$-193.88M
Operating Income / Loss	$-161.2M	$-57.64M	$-161.2M
Cost of Revenue
Net Cash Flow	$-23.06M	$-24.34M	$-23.06M
PE Ratio